Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.04 USD
-2.37 (-2.13%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $109.52 +0.48 (0.44%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
WIll Allergan (AGN) Beat Estimates This Earnings Season?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.
Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Guardant Health (GH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Koppers, Alaska Air, Guess?, Lionsgate and Jazz Pharmaceuticals
Invest in These 5 High Earnings Yield Stocks Right Away
by Zacks Equity Research
Here are five stocks with high earnings yield that can be picked for a solid portfolio.
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
Why the Earnings Surprise Streak Could Continue for Jazz (JAZZ)
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment
by Zacks Equity Research
Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.
5 High Earnings Yield Stocks to Buy for a Rewarding Portfolio
by Zacks Equity Research
Here are five stocks with high earnings yield that can be picked for a solid portfolio.
Jazz Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Jazz Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.